We have a winner: Boehringer Ingelheim’s Ofev takes #FierceMadness ad championship

Boehringer Ingelheim TV ad for Ofev
Boehringer Ingelheim's emotional TV ad and branded ad debut for IPF drug Ofev took the #FierceMadness ad championship. (Boehringer Ingelheim)

In a back-and-forth final matchup, Boehringer Ingelheim’s ad campaign for Ofev pulled away from GlaxoSmithKline’s Trelegy to land the #FierceMadness ad tournament crown.

By a vote of 4,225-2,181, the Ofev campaign, built around the story of a boxer and his father who has idiopathic pulmonary fibrosis,  won on emotional strength and the power of Boehringer Ingelheim to get the word out to vote.

That’s in part because the Ofev ad only ran on addressable TV—including DirecTV and Comcast—from January through March. Some voters said they could not find the ad online, but that’s because BI’s campaign was a focused digital streaming effort that didn’t extend to searchable online media.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

See the Ofev TV ad here: https://bit.ly/2MdW7Fq 

Those who did see the work noted the emotional effectiveness of the ad, the IPF journey and the connection to family. One person wrote, “It is about the patient journey—and with IPF it is not a journey that the patient embarks on alone. Family is affected also.” Another said, "Greater need! First to build awareness about a RARE, but rising disease state! Great visuals and appeals to the senses!"

Some votes for Ofev were also votes against the polarizing jingle “Easy as 1,2,3” play on Jackson Five tune for Trelegy. One commenter said, “Catchy as it may be, it's a canned song vs original content that invokes sympathy/empathy.... Humanity is the winner here.”

Thanks to all of this year's voters, and especially those who offered their perspective in the comment sections. #FierceMadness will be back next February with an all-new NCAA-style tournament—stay tuned!

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.